Cornerstone Planning Group’s Charles River Laboratories CRL Stock Holding History

Cornerstone Planning Group’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.97K	Hold	9	–	–	﹤0.01%	1332
2026 Q1	$1.67K	Sell	9 -2	-18%	-$371	﹤0.01%	1336
2025 Q4	$2.39K	Hold	11	–	–	﹤0.01%	1158
2025 Q3	$1.97K	Hold	11	–	–	﹤0.01%	1166
2025 Q2	$1.84K	Sell	11 -17	-61%	-$2.27K	﹤0.01%	969
2025 Q1	$3.05K	Buy	28 +15	+115%	+$2.52K	﹤0.01%	877
2024 Q4	$2.16K	Sell	13 -11	-46%	-$2.12K	﹤0.01%	780
2024 Q3	$4.42K	Sell	24 -4	-14%	-$831	﹤0.01%	588
2024 Q2	$6.34K	Sell	28 -12	-30%	-$2.72K	﹤0.01%	525
2024 Q1	$9.34K	Sell	40 -35	-47%	-$8.36K	﹤0.01%	420
2023 Q4	$17.7K	Buy	75 +25	+50%	+$4.92K	0.01%	332
2023 Q3	$9.8K	Sell	50 -15	-23%	-$3.08K	﹤0.01%	424
2023 Q2	$13.7K	Buy	+65	New	+$12.9K	0.01%	541
2022 Q4	$19.9K	Buy	+85	New	+$18.6K	0.01%	441

Other funds holding CRL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.65B AUM 9.66% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

VBA

Van Berkom & Associates Montreal, Quebec, Canada $3.1B AUM 12.88% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Cornerstone Planning Group's CRL Position: Q2 2026 in Review

Cornerstone Planning Group held its Charles River Laboratories (CRL) position steady in Q2 2026 at 9 shares worth $1.97K. The position accounts for ﹤0.01% of the portfolio, ranked #1332.

Cornerstone Planning Group first reported a position in CRL in Q4 2022 and has held it in 14 quarters since. The position peaked at $19.9K in Q4 2022. 287 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

Cornerstone Planning Group held 9 shares of Charles River Laboratories worth $1.97K as of Q2 2026.
Cornerstone Planning Group left its Charles River Laboratories share count unchanged in Q2 2026.
Charles River Laboratories made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q2 2026, its #1332 holding.
Cornerstone Planning Group first reported a position in Charles River Laboratories in Q4 2022 and has held it in 14 quarters since.
Cornerstone Planning Group's Charles River Laboratories position peaked at $19.9K in Q4 2022.
287 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Cornerstone Planning Group's 13F filing for Q2 2026, filed 29 Jul 2026.